ArticleCancers2021

Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets.

Tuba N Gide et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.